[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Relay Therapeutics Inc (RLAY)

Relay Therapeutics Inc (RLAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,787,655
  • Shares Outstanding, K 191,586
  • Annual Sales, $ 15,360 K
  • Annual Income, $ -276,480 K
  • EBIT $ -296 M
  • EBITDA $ -296 M
  • 60-Month Beta 1.69
  • Price/Sales 246.42
  • Price/Cash Flow N/A
  • Price/Book 5.88

Options Overview Details

View History
  • Implied Volatility 104.48% (+9.16%)
  • Historical Volatility 52.93%
  • IV Percentile 15%
  • IV Rank 4.73%
  • IV High 759.75% on 09/12/25
  • IV Low 71.91% on 05/20/26
  • Expected Move (DTE 11) 1.02 (5.12%)
  • Put/Call Vol Ratio 1.47
  • Today's Volume 1,832
  • Volume Avg (30-Day) 4,657
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 28,663
  • Open Int (30-Day) 25,264
  • Expected Range 18.92 to 20.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.38
  • Number of Estimates 4
  • High Estimate $-0.35
  • Low Estimate $-0.41
  • Prior Year $-0.43
  • Growth Rate Est. (year over year) +11.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.71 +12.59%
on 07/28/26
20.71 -3.72%
on 08/10/26
-0.06 (-0.32%)
since 07/10/26
3-Month
11.62 +71.60%
on 05/20/26
20.79 -4.09%
on 07/09/26
+7.18 (+56.27%)
since 05/08/26
52-Week
3.15 +533.02%
on 08/11/25
20.79 -4.09%
on 07/09/26
+16.72 (+519.25%)
since 08/08/25

Most Recent Stories

More News
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

Selected  z ovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine - sensitive patients expected to initiate in early 2027, subject...

RLAY : 19.94 (+0.86%)
Relay Therapeutics Reports Another Loss as Pipeline Advances Remain the Only Narrative

Barchart Research What to Expect from RLAY Earnings RLAY Generated August 5, 2026 Current Price $19.69 EPS Estimate $$-0.41 Consensus Rating Strong Buy Average Move 6.98% Relay Therapeutics Reports Another...

RLAY : 19.94 (+0.86%)
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 19.94 (+0.86%)
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 19.94 (+0.86%)
Relay Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 19.94 (+0.86%)
Relay Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 19.94 (+0.86%)
Rising Bond Yields Weigh on Stocks

The S&P 500 Index ($SPX ) (SPY ) today is down -0.68%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.34%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.95%. June E-mini S&P futures...

ALK : 47.26 (-5.40%)
SNDK : 1,237.92 (+2.12%)
HL : 17.55 (+4.15%)
CDE : 18.15 (+4.37%)
ADI : 383.92 (-1.54%)
STUB : 8.78 (-1.90%)
CRWV : 88.19 (-2.74%)
STX : 800.99 (-1.45%)
WDC : 438.34 (+0.93%)
AMD : 469.56 (-2.86%)
SCCO : 200.11 (+0.53%)
SPY : 773.03 (-0.03%)
Stocks Pressured by Tech Weakness and Rising Bond Yields

The S&P 500 Index ($SPX ) (SPY ) today is down -0.35%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.19%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.45%. June E-mini S&P futures...

ALK : 47.26 (-5.40%)
ADI : 383.92 (-1.54%)
STUB : 8.78 (-1.90%)
CRWV : 88.19 (-2.74%)
STX : 800.99 (-1.45%)
WDC : 438.34 (+0.93%)
AMD : 469.56 (-2.86%)
SPY : 773.03 (-0.03%)
ADSK : 256.07 (+2.81%)
AAL : 15.00 (-5.90%)
QQQ : 720.87 (-0.30%)
TOL : 150.00 (-3.28%)
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies

Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and patient-reported...

RLAY : 19.94 (+0.86%)
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

FDA Breakthrough Therapy designation granted to  zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer Presented zovegalisib...

RLAY : 19.94 (+0.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Relay Therapeutics Inc. is a clinical-stage precision medicines company. It focuses on enhancing small molecule therapeutic discovery in targeted oncology. The company's product pipeline consist RLY-1971, RLY-4008 and RLY-PI3K1047 which are in clinical stage. Relay Therapeutics Inc. is based in Cambridge,...

See More

Key Turning Points

3rd Resistance Point 21.93
2nd Resistance Point 21.32
1st Resistance Point 20.63
Last Price 19.94
1st Support Level 19.33
2nd Support Level 18.72
3rd Support Level 18.03

See More

52-Week High 20.79
Last Price 19.94
Fibonacci 61.8% 14.05
Fibonacci 50% 11.97
Fibonacci 38.2% 9.89
52-Week Low 3.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.